SOURCE: Daxor Corp.

March 05, 2007 08:30 ET

A Major Study Compares Direct Blood Volume Measurement Using the BVA-100 With the BNP Test for Managing Fluid Therapy in the Intensive Care Unit

NEW YORK, NY -- (MARKET WIRE) -- March 5, 2007 -- A study entitled "Does Blood Volume and BNP Correlate?" was presented at the annual Critical Care Conference in Orlando. Daxor's (AMEX: DXR) BVA-100 was used for the study. The senior authors were Susan M. Apte, Mihae Yu, et al. from Queen's Hospital, Hawaii, the largest hospital in the Hawaiian Islands. B-type natriuretic peptide (BNP) is a cardiac neurohormone predominantly released from the ventricles in response to stretch of ventricular myocytes or increases in wall tension. BNP is widely used for diagnosing the presence of heart failure. Values of BNP have been used to guide physicians in determining fluid and diuretic therapy for patients with cardiac dysfunction. The BNP test is manufactured by Biosite. The Biosite Company makes no claim that BNP is a measure of the blood volume status of the patient. However, many physicians use BNP levels as a guide to administering or withholding fluids from patients in heart failure.

30 surgical intensive care patients had a total of 58 blood volume measurements obtained simultaneously with BNP measurements. The diagnosis of the patients included septic shock, trauma, and hemorrhagic shock. The study concluded that there was no correlation between BNP levels and the blood volume status of the patient. This is the largest study reported to date where blood volumes were actually measured simultaneously with BNP levels in critically ill patients. The authors concluded that blood volume measurements may guide in optimizing fluid measurements when there is uncertainty about the intravascular volume status of complex patients.

This study confirms the clinical impression of a number of physicians that BNP measurements should not be relied upon as a guide in fluid therapy. Reliance upon elevated BNP levels as a marker of an expanded blood volume could theoretically result in the inappropriate withholding of fluid or blood transfusions in patients with a severely reduced blood volume.

Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website

Contact Information

  • Contact Information:
    Stephen Feldschuh
    Chief Operating Officer
    Email Contact

    Diane Meegan
    Investor Relations
    Email Contact